These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7533518)

  • 1. The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
    Lind MJ; Gumbrell L; Cantwell BM; Millward MJ; Simmonds D; Proctor M; Chapman F; McCann E; Middleton I; Calvert AH
    Br J Cancer; 1995 Mar; 71(3):610-3. PubMed ID: 7533518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
    Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
    Piccart MJ; Bruning P; Wildiers J; Awada A; Schornagel JH; Thomas J; Tomiak E; Bartholomeus S; Witteveen PO; Paridaens R
    Ann Oncol; 1995 Sep; 6(7):673-7. PubMed ID: 8664188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
    Gurney H; Harnett P; Stuart-Harris R; Kefford R
    Eur J Cancer; 1995 Oct; 31A(11):1773-7. PubMed ID: 8541098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
    Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
    Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
    J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
    Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
    Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
    Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II clinical trial of epirubicin and paclitaxel followed by granulocyte colony-stimulating factor in a 2-week schedule in patients with advanced or metastatic breast cancer.
    Ries F; Duhem C; Kleiber K; Dicato M
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-48-S17-51. PubMed ID: 9374093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma.
    Fornasiero A; Ghiotto C; Daniele O; Favaretto AG; D'Amanzo P; Ziade A
    Tumori; 2001; 87(4):223-8. PubMed ID: 11693799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer.
    Kaya AO; Coskun U; Buyukberber S; Benekli M; Tekin E; Cifter C; Ozturk B; Yildiz R; Yaman E; Uner A; Yamac D
    J BUON; 2010; 15(2):248-54. PubMed ID: 20658717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
    Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
    J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.
    Reichardt P; Tilgner J; Hohenberger P; Dörken B
    J Clin Oncol; 1998 Apr; 16(4):1438-43. PubMed ID: 9552049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
    Ghavamzadeh A
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S66-8. PubMed ID: 2347052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
    J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group study.
    Fountzilas G; Skarlos D; Katsohis C; Pavlidis N; Giannakakis T; Bafaloukos D; Fahantidis E; Klouvas G; Beer M; Kosmidis P
    Med Pediatr Oncol; 1995 Jan; 24(1):23-8. PubMed ID: 7526143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.